theStockRadio.com is pleased to announce a new with , of (.V: )


Med_BioGene_-_Logo

Med BioGene Inc. (MBI) is a life science company based in Vancouver, British Columbia, that is currently focused on managing the license and rights to GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung. MBI’s common shares are traded on the TSX Exchange. For more information regarding MBI, please visit www.medbiogene.com. For more information regarding Precision, please visit www.precisiontherapeutics.com.

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE